

1 Endocannabinoids in *Caenorhabditis elegans* are essential for the
2 mobilization of cholesterol from internal reserves

3

4 **Galles, Celina^{a#}, Prez, Gastón M.^{a#}, Penkov, Sider^{b#}, Boland, Sebastian^c, Porta, Exequiel O.**
5 **J.^d, Altabe, Silvia G.^a, Labadie, Guillermo R.^c, Schmidt, Ulrike^e, Knölker, Hans-Joachim^e,**
6 **Kurzchalia, Teymuraz V.^{b*} and de Mendoza, Diego^{a*}**

7

8 ^aLaboratorio de Fisiología Microbiana, Instituto de Biología Molecular y Celular de Rosario (IBR),
9 CONICET, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario,
10 2000, Rosario, Argentina.

11 ^bMax Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.

12 ^cDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health,
13 Boston, MA 02115, U.S.A.


14 ^dInstituto de Química Rosario (IQUIR), CONICET, Facultad de Ciencias Bioquímicas y
15 Farmacéuticas, Universidad Nacional de Rosario 2000, Rosario, Argentina.

16 ^eDepartment Chemie, Technische Universität Dresden, Bergstr. 66, 01069 Dresden, Germany.

17

18 [#]These authors contributed equally to this work


19 ^{*}For correspondence: demendoza@ibr-conicet.gov.ar or kurzchalia@mpi-cbg.de



21

22 **Supplementary Figure 1. Sterol-depletion leads to dauer-like morphology in *fat-3* mutants.**
23 N2 worms grown in cholesterol-depleted media reach adulthood (upper left panel), while *fat-3*
24 worms mostly arrest as dauer-like animals (upper right panel). Both strains exclusively form adults
25 in the presence of cholesterol (lower panels). Representative images from at least three
26 experiments. Nomarski microscopy. Scale bars, 0.1 mm.

27




28

29

30 **Supplementary Figure 2. Arachidonic acid-deficient mutants *daf-7;fat-4* exhibit a Daf-c**
 31 **phenotype at 20 °C, which can be overcome by endocannabinoid supplementation. (a)** As
 32 opposed to *daf-7* and *fat-4* strains, double mutant *daf-7;fat-4* forms ~85% dauers at 20 °C, and
 33 addition of DA suppresses dauer formation almost completely. One-way analysis of variance,
 34 $p < 0.001$. (*) indicates statistically significant difference with *daf-7*, multiple comparison by Holm-
 35 Sidak method, $p < 0.05$ for all conditions. Bars represent mean values and error bars represent
 36 standard errors. The number of independent experiments is $n = 3$ for all conditions. [DA] = 90 nM.
 37 **(b)** Addition of excess cholesterol, 2-AG and noladin effectively reduces dauer formation in each
 38 case. One-way analysis of variance $p < 0.001$. (*) indicates statistically significant difference with
 39 cholesterol 13 μM, multiple comparison by Holm-Sidak method, $p < 0.05$ for cholesterol 130 μM
 40 and $p < 0.001$ for the remaining conditions. Bars represent mean values and error bars represent
 41 standard errors. The number of independent experiments is $n = 3$ for all conditions, except for 2-
 42 AG where $n = 9$. [DA] = 90 nM. [2-AG] = 50 μM. [Noladin] = 100 μM.

43


44



45

46 **Supplementary Figure 3. Endocannabinoids cannot substitute for dafachronic acid.** *daf-*
 47 *9(dh6)* mutant worms are unable to produce DAs, and hence form dauer larvae. Supplementing
 48 the food with DA suppresses this arrest. However, addition of endocannabinoids 2-AG and AEA
 49 does not suppress this phenotype. Kruskal-Wallis One Way Analysis of Variance on Ranks,
 50 $p < 0.001$, All Pairwise Multiple Comparison Procedures (Tukey's Method), (*) indicates
 51 statistically significant difference with control (solvent) $p < 0.05$. Bars represent mean values and
 52 error bars represent Standard Errors. The amount of independent experiments is $n = 6$ for all
 53 conditions. [DA] = 90 nM. [2-AG] or [AEA] = 50 μ M.


54



55

56


57 **Supplementary Figure 4. RNAi for *faah-1* effectively reduces the Daf-c phenotype of *daf-7***
58 **strain at 20 °C.** t-test, $p < 0.001$. (*) indicates statistically significant difference with empty vector
59 control (EV). Bars represent mean values and error bars represent Standard Errors. The amount of
60 independent experiments is $n=6$ for both conditions.



61

62 **Supplementary Figure 5. Fatty acid synthesis and elongation in *C. elegans*.** *C. elegans* is
 63 capable of synthesizing long-chain fatty acids from either acetyl-CoA precursors or dietary
 64 palmitate. Acetyl-CoA is condensed with HCO_3^- to generate malonyl-CoA by the acetyl-CoA
 65 carboxylase enzyme. Malonyl-CoA consecutively incorporates two carbon units for its elongation
 66 up to palmitate by the enzyme fatty acid synthase. Several elongases, LET-767 3-ketoacyl-CoA-
 67 reductase, 3-hydroxyacyl-CoA dehydratase and enoyl reductase activities and seven desaturases
 68 (FAT-1 through FAT-7) are necessary for LCFA remodeling and PUFA synthesis. The synthesis
 69 from Isobutyryl-CoA to C13iso is also performed by fatty acid synthase enzyme. Then, C13iso is
 70 further elongated to longer BCFAs (C15iso and C17iso) by the action of elongase enzymes ELO-
 71 5/6 and LET-767. The point of action of LET-767, the RNAi-targeted enzyme evaluated in this
 72 study, is indicated and highlighted with a green box.

73




74

75

76 **Supplementary Figure 6. Simplified biosynthesis pathway for d17iso-GlcCeramide from**
 77 **branched-chain fatty acid precursors in *C. elegans*.** The enzymes involved in this pathway are
 78 depicted in a simplified scheme. Ceramide glucosyltransferase enzymes (CGT-1,3) are highlighted
 79 with a green box and the point of action of PDMP is indicated. Not shown are the enzymatic steps
 80 for the conversion of d17iso-sphinganine to d17iso-ceramide.

81



82

83 **Supplementary Figure 7. Deficiency of iso-branched fatty acids leads to a high incidence of**
84 **dauers in *daf-7* background mutants.** *let-767* RNAi treated wild-type worms do not display a
85 dauer formation phenotype. However, *daf-7* worms treated with *let-767* RNAi exhibit a strong
86 dauer phenotype (indicated with arrowheads), in contrast to *daf-7* animals treated with an empty
87 vector control. Representative images from at least three experiments. Scale bars, 0.5 mm.

88

89 **Supplementary Table 1. LC-MS/MS detection and absolute quantification of 2-AG and AEA**
90 **in lipid extracts of N2, *daf-7*, *fat-3* and *daf-7;fat-3* worms supplemented with methyl-AA (50**
91 **μ M). *fat-3* and *daf-7;fat-3* mutants are capable of synthesizing 2-AG and AEA from the**
92 **methyl-AA supplement.**

	2-AG (pg/mg protein)	AEA (pg/mg protein)
N2	853.62 \pm 294.00	19.74 \pm 11.28
<i>daf-7</i>	1654.63 \pm 745.22	17.93 \pm 9.62
<i>fat-3</i> + methyl-AA	964.58	8027.85
<i>daf-7;fat-3</i> + methyl-AA	1210.5	10226.7

93

94

95 **Supplementary Table 2. LC-MS/MS detection and absolute quantification of 2-AG in lipid**
96 **extracts of synchronized N2 L4 worms grown for 72h at 20 °C in the presence of cholesterol**
97 **at the standard working concentration (13 μM) and under complete depletion of this sterol**
98 **(0 μM).**

[cholesterol]	[2-AG]
13 μM	2294.025±177.92 (pg/mg protein)
0 μM	4868.33± 438.08 (pg/mg protein) (*)

99

100 Measurements are informed as (mean values ± standard deviations). (*) indicates statistically
101 significant difference with [cholesterol]=13 μM condition. t-test, p-value=0.002. The amount of
102 independent experiments is n=3 for [cholesterol]=13 μM and n=2 for [cholesterol]= 0 μM.

103

104

105

106

107

108

109

110 **Supplementary Table 3. *let-767* RNAi significantly decreases the mmBCFA content (15:0iso**
 111 **and 17:0iso) of *daf-7*.**

FATTY ACID	Empty vector	<i>let-767</i> RNAi	p-value
14:0	2.28 ± 0.41	2.73 ± 0.41	0.246
15:0iso	6.83 ± 0.20	3.43 ± 0.27*	<0.001
15:0	0.08 ± 0.03	0.22 ± 0.1	0.074
16:0	4.30 ± 0.97	6.52 ± 2.49	0.224
17:0iso	4.38 ± 0.11	2.15 ± 0.37*	<0.001
18:0	5.19 ± 0.52	7.38 ± 0.33*	0.004
18:1 (n-9)	7.32 ± 1.19	3.41 ± 0.16*	0.005
18:1 (n-7)	19.22 ± 3.20	20.77 ± 3.29*	0.045
20:3 (n-6)	1.88 ± 0.24	1.99 ± 0.18	0.564
20:4 (n-6)	1.31 ± 0.40	1.10 ± 0.06	0.414
20:3 (n-3)	0.22 ± 0.08	0.10 ± 0.02	0.070
20:4 (n-3)	1.81 ± 0.14	2.18 ± 0.56	0.308
20:5 (n-3)	6.32 ± 1.21	6.79 ± 1.23	0.657

112

113 Relative percentage values (mean ± standard deviation) of fatty acids measured by GC/MS
 114 analysis of *daf-7* worms grown on control conditions (empty vector) or *let-767* RNAi. (*) indicates
 115 significant difference with empty vector. t-test, $\alpha=0.05$. The amount of independent experiments
 116 is n=3 for empty vector and *let-767* RNAi.

117

118 **Supplementary Table 4. GC/MS analysis of fatty acid methyl-esters in *daf-7* mutants grown**
 119 **on empty vector or *let-767* RNAi in the absence or presence of 2-AG.**

	EV	<i>let-767</i> RNAi	<i>let-767</i> RNAi+2-AG
SFA	13.42 ± 1.42	19.55 ± 2.74 (*)	17.95 ± 1.27
mmBCFA	12.55 ± 1.28	7.66 ± 1.73 (*)	6.92 ± 1.36
MUFA	34.88 ± 3.88	36.54 ± 4.36	34.28 ± 8.37
PUFA	23.42 ± 1.23	22.79 ± 1.69	25.68 ± 3.59
Cyclopropanes	15.74 ± 4.87	13.45 ± 3.30	15.18 ± 4.87

120

121 Endocannabinoid treatment does not revert the drop in mmBCFAs levels induced by *let-767*
 122 RNAi. The values represent the relative percentage of each fatty acid species (mean ± standard
 123 deviation). The number of independent experiments is n=3 for empty vector (EV) and *let-767*
 124 RNAi, and of n=2 for *let-767* RNAi+2-AG. SFA: straight chain saturated fatty acids; mmBCFA:
 125 mono-methyl branched chain fatty acids; MUFA: mono-unsaturated fatty acids; PUFA:
 126 polyunsaturated fatty acids. (*) indicates statistically significant difference with empty vector
 127 control. One-way analysis of variance, p<0.05. [2-AG]=50 μM.

128

129